-
Major quake rocks Colombia and neighbors, 18 confirmed dead
-
Barcelona turn down PSG offer for Torres
-
Brazil aircraft maker Embraer raises outlook after record revenue
-
Buildings collapse as major quake rocks Colombia and neighbors
-
Drought forces water restrictions across nearly 70 percent of France
-
Meta releases new AI model as Zuckerberg lays out vision
-
Europe wary as gas stocks languish at lows while winter looms
-
Freedom Holding Corp. Reports 40% Increase in Quarterly Revenue to $732.5 Million
-
OFunded Enters the Prop Trading Market With Broker-Backed Infrastructure From OFinancial Markets
-
What next for beleaguered FIFA president Infantino?
-
Stocks mostly flat with focus on US inflation
-
Greece contains new wind-driven fire near Athens
-
UK radio broke rules in announcing king's death: watchdog
-
Massive shake-up of Hungary media after Orban's exit
-
Europe braces for another summer heatwave
-
Days of heavy rain leave at least 16 dead in Philippines
-
Tentoglou keep bid for fourth Euro title on course, Nowicki misses out
-
Bezos consortium nears deal to buy Liverpool stake: report
-
MEXC Sponsors Yohani's Colombo Concert, Bridging Sri Lankan Culture and Global Digital Finance
-
Stocks mostly rise with focus on US inflation
-
Parts of Germany's Rhine could become unnavigable, group warns
-
Days of heavy rain leave at least 13 dead in Philippines
-
Base Markets Appoints Nazim Moussaoui as Head of Premium Clients and Partnerships
-
Ex-Thai MP shoots dead local official over money row
-
US, South Korea to drill for new threats from North
-
July was Spain's hottest month on record: weather agency
-
SCANDIC TRADE Ultimate 2.6 är färdigutvecklat – SNC SCANDIC ECO-Systemet är nu komplett
-
SCANDIC TRADE Ultimate 2.6 jest gotowy – system SNC SCANDIC ECO jest kompletny
-
SCANDIC TRADE Ultimate 2.6 je hotový – systém SNC SCANDIC ECO je kompletní
-
تم الانتهاء من تطوير SCANDIC TRADE Ultimate 2.6 – وبذلك أصبح نظام SNC SCANDIC ECO متكاملاً
-
SCANDIC TRADE Ultimate 2.6が完成――SNC SCANDIC ECOシステムが完成しました
-
स्कैंडिक ट्रेड अल्टीमेट 2.6 अब पूरा हो गया है – SNC स्कैंडिक इको-सिस्टम अब पूरी तरह से चालू है।
-
Record July heat in regions home to 900 mn people: AFP analysis
-
Embattled Infantino target of letter from three confederations
-
SCANDIC TRADE Ultimate 2.6이 완성되었습니다 – SNC SCANDIC ECO-시스템이 완성되었습니다
-
SCANDIC TRADE Ultimate 2.6 已正式推出——SNC SCANDIC ECO 系統現已完整建置
-
SCANDIC TRADE Ultimate 2.6 завершена — экосистема SNC SCANDIC стала полноценной
-
SCANDIC TRADE Ultimate 2.6 завершено — екосистема SNC SCANDIC стала повноцінною
-
SCANDIC TRADE Ultimate 2.6 is now complete – the SNC SCANDIC ECO-System is now fully operational
-
Eighth day of wildfires in Indonesian national park
-
Chinese AI drives price competition among US labs
-
One woman confirmed dead in western Canada wildfire
-
Indian students step up exam protests in Jharkhand
-
Energy transition threatens to wipe Dutch village from map
-
Stopped broadcast, layoffs: Hungary media eyes post-Orban renewal
-
Self-taught Turkish 'linguist' keeps dead language alive
-
Typhoon Dolphin weakens but disrupts travel in east China
-
Asian stocks track Wall St higher after US job losses ease rate fears
-
Pakistan brickmakers scorched by sun above and fire below
-
Western Europe experienced hottest June-July on record: EU monitor
Treatment improves cognition in Down Syndrome patients
A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.
However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.
"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.
Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.
Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.
Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.
GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.
"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.
- Mice research -
The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.
They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.
The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.
A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.
They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.
Cognition and smell tests were carried out during the treatment, as were MRI scans.
Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.
"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.
The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.
- 'Improve quality of life' -
The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".
"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.
A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.
"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.
Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".
He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.
It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.
"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."
T.Bondarenko--BTB